A Phase II Trial of Carboplatin (CBDCA) in Relapsed or Refractory Acute Myeloid Leukemia

Closed

Phase

Accrual

82%

Published

Abbreviated Title

A Phase II Trial of Carboplatin (CBDCA) in Relapsed or Refractory Acute Myeloid Leukemia

Activated

11/15/1989

Closed

10/15/1992

Publication Information Expand/Collapse

1995

Carboplatin infusion in relapsed and refractory acute myeloid leukemia - A Southwest Oncology Group trial.

JL Welborn;KJ Kopecky;FJ Meyers;R Veith;M Shurafa;JH Doroshow;SP Balcerzak;FR Appelbaum Leukemia 9:1126-1129

1994

CD56: A determinant of extramedullary and central nervous system (CNS) involvement in acute myeloid leukemia (AML). Modern Pathology 7(1):120A (#695)

AA Scott;KJ Kopecky;TM Grogan;DR Head;FA Troy, II;J Mullen;J Ya;FR Appelbaum;KS Theil;CL Willman Intl Academy of Pathology 120A(#695)/Lab Investigation 70(1):120A(#695)

HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3

AA Scott;DR Head;KJ Kopecky;FR Appelbaum;KS Theil;MR Grever;I-M Chen;MH Whittaker;BB Griffith;JD Licht;S Waxman;MM Whalen;AD Bankhurst;LC Richter;TM Grogan;CL Willman Blood 84(1):244-255

1993

Identification and characterization of a previously unrecognized form of acute leukemia co-expressing myeloid and natural killer (NK) cell-associated antigens (CD56).

AA Scott;DR Head;K Theil;LM Chen;MH Whittaker;CL Willman International Academy of Pathology 68:100A(#575)